Hadasit, together with strategic partners, has established a number of start-up companies based on technologies fully or partially developed at Hadassah Medical Organization.
Hadasit Start-Up Companies
 |
Exalenz
Point-of-care diagnostics of gastrointestinal and liver diseases. |
 |
ConjuGate
A unique, non-toxic and cost effective treatment against systemic fungal infections.
|
 |
DMMT
Improving the repair of long bone fractures.
|
 |
Enhancing the power of cell therapy. |
 |
GVT
Unique vector delivery systems in gene therapy and molecular biology. |
 |
TheraVir Management
Fighting cancer with oncolytic viruses.
|
Hadasit has spun-off 9 of its companies into a subsidiary named Hadasit Bio-Holdings Ltd. ("HBL"). Strict criteria relating to the stage of the technological advancement, strength of intellectual property and market potential were applied in the selection process. During December 2005, HBL was floated via an Initial Public Offering (IPO) on the Tel Aviv Stock Exchange. Please visit:
www.tase.co.il /quote: HDST.
 |
Cell Cure NeuroSciences
Revolutionizing the treatment of neurological diseases through human embryonic stem cell therapies.
|
 |
InCure
A diagnostic and therapeutic platform technology for diagnosis and therapy of tumor malignancies.
|
 |
KAHR
Immunotherapeutic proteins for the management of autoimmune diseases.
|
 |
Tissue engineering through fibrin platform technologies.
|
 |
Protab
Tipping the Balance towards More Effective Treatments for Autoimmune Diseases. |
 |
Thrombotech
Distinctive technologies for the management of stroke and heart attack. |
 |
TK Signal
Revolutionary radiology-based compounds for diagnosis, monitoring and treatment of cancer.
|
 |
Tolarex
Vaccination for the management and treatment of GVHD, inflammatory and autoimmune diseases. |
 |
Verto
A disease-specific ex-vivo treatment for SLE.
|
